Truist Securities maintains Buy rating on Viking Therapeutics, $87 price target

Truist Securities maintained their Buy rating on Viking Therapeutics's stock with a price target of $87.00.The price target implies an upside of 113.0% from the Sep 22 close of $40.85.Key takeaways from the analyst noteStrong Clinical Pipeline: Viking Therapeutics boasts a robust clinical program w…